We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fastly (FSLY) Set to Report Q1 Earnings: What to Expect?
Read MoreHide Full Article
Fastly (FSLY - Free Report) is set to release first-quarter 2021 results on May 5.
For the quarter, the company expects revenues between $83 million and $86 million. Moreover, adjusted loss is projected between 9 cents and 13 cents per share.
The Zacks Consensus Estimate is currently pegged at a loss of 11 cents per share, which has been unchanged over the past 30 days. The company had reported a loss of 6 cents per share in the year-ago quarter.
Moreover, the consensus mark for the top line is currently pegged at $85.2 million, implying 35.3% growth from the figure reported in the year-ago quarter.
Markedly, Fastly’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, missing the same in the remaining one, the average earnings surprise being 16%.
Fastly’s first-quarter 2021 results are expected to benefit from higher bandwidth usage. Moreover, an expanding clientele is expected to have driven top-line growth in the to-be-reported quarter.
Markedly, customer count increased to 2,084 from 2,047 at the end of the fourth-quarter. Moreover, total-enterprise customer count increased from 313 in the third quarter to 324 in the fourth quarter.
Moreover, solid contribution from Signal Sciences is expected to have benefited to Fastly’s top-line growth in the to-be-reported quarter.
What Our Model Indicates
Per the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
Fastly has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Here are a few companies worth considering as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases:
Fair Isaac (FICO - Free Report) has an Earnings ESP of +15.94% and is #2 Ranked.
Waters Corporation (WAT - Free Report) has an Earnings ESP of +2.94% and a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Fastly (FSLY) Set to Report Q1 Earnings: What to Expect?
Fastly (FSLY - Free Report) is set to release first-quarter 2021 results on May 5.
For the quarter, the company expects revenues between $83 million and $86 million. Moreover, adjusted loss is projected between 9 cents and 13 cents per share.
The Zacks Consensus Estimate is currently pegged at a loss of 11 cents per share, which has been unchanged over the past 30 days. The company had reported a loss of 6 cents per share in the year-ago quarter.
Moreover, the consensus mark for the top line is currently pegged at $85.2 million, implying 35.3% growth from the figure reported in the year-ago quarter.
Markedly, Fastly’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, missing the same in the remaining one, the average earnings surprise being 16%.
Fastly, Inc. Price and EPS Surprise
Fastly, Inc. price-eps-surprise | Fastly, Inc. Quote
Fastly’s first-quarter 2021 results are expected to benefit from higher bandwidth usage. Moreover, an expanding clientele is expected to have driven top-line growth in the to-be-reported quarter.
Markedly, customer count increased to 2,084 from 2,047 at the end of the fourth-quarter. Moreover, total-enterprise customer count increased from 313 in the third quarter to 324 in the fourth quarter.
Moreover, solid contribution from Signal Sciences is expected to have benefited to Fastly’s top-line growth in the to-be-reported quarter.
What Our Model Indicates
Per the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
Fastly has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Here are a few companies worth considering as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases:
CDW Corporation (CDW - Free Report) has an Earnings ESP of +0.51% and is Zacks #2 Ranked. You can see the complete list of today’s Zacks #1 Rank stocks here.
Fair Isaac (FICO - Free Report) has an Earnings ESP of +15.94% and is #2 Ranked.
Waters Corporation (WAT - Free Report) has an Earnings ESP of +2.94% and a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>